Circassia broke the licensing agreement with AstraZeneca

British pharmaceutical company Circassia has announced the termination of cooperation with AstraZeneca in the development and commercialization of two drugs for the treatment of COPD in the United States. This writes The Pharma Letter.

Under the terms of the agreement in 2017, the company conducted joint development of inhaled drugs acridine bromide and formoterol fumarate+ acridine bromide. Circassia also received the option to buy the rights to these drugs in the United States.

Now, however, AstraZeneca will have rights to medicines, as well as some additional assets. In turn, Circassia will be able to get rid of the debt owed to AstraZeneca.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]